Xencor price target raised to $36 from $34 at Wedbush

Wedbush raised the firm’s price target on Xencor to $36 from $34 and keeps an Outperform rating on the shares. With robust partnership developments, promising early data for vudalimab, and a strong cash position to support ongoing programs, Wedbush believes Xencor shares are attractive at current levels.